Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma

  • Ju Gao1,
  • Minzhi Yin2,
  • Yiping Zhu1,
  • Ling Gu1,
  • Yanle Zhang1,
  • Qiang Li1,
  • Cangsong Jia1 and
  • Zhigui Ma1Email author
BMC Cancer201313:471

https://doi.org/10.1186/1471-2407-13-471

Received: 6 February 2013

Accepted: 4 October 2013

Published: 10 October 2013

Abstract

Backgroud

Activation of the protein kinase B/mammalian target of rapamycin (AKT/mTOR) pathway has been demonstrated to be involved in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated tumorigenesis in anaplastic large cell lymphoma (ALCL) and correlated with unfavorable outcome in certain types of other cancers. However, the prognostic value of AKT/mTOR activation in ALCL remains to be fully elucidated. In the present study, we aim to address this question from a clinical perspective by comparing the expressions of the AKT/mTOR signaling molecules in ALCL patients and exploring the therapeutic significance of targeting the AKT/mTOR pathway in ALCL.

Methods

A cohort of 103 patients with ALCL was enrolled in the study. Expression of ALK fusion proteins and the AKT/mTOR signaling phosphoproteins was studied by immunohistochemical (IHC) staining. The pathogenic role of ALK fusion proteins and the therapeutic significance of targeting the ATK/mTOR signaling pathway were further investigated in vitro study with an ALK + ALCL cell line and the NPM-ALK transformed BaF3 cells.

Results

ALK expression was detected in 60% of ALCLs, of which 79% exhibited the presence of NPM-ALK, whereas the remaining 21% expressed variant-ALK fusions. Phosphorylation of AKT, mTOR, 4E-binding protein-1 (4E-BP1), and 70 kDa ribosomal protein S6 kinase polypeptide 1 (p70S6K1) was detected in 76%, 80%, 91%, and 93% of ALCL patients, respectively. Both phospho-AKT (p-AKT) and p-mTOR were correlated to ALK expression, and p-mTOR was closely correlated to p-AKT. Both p-4E-BP1 and p-p70S6K1 were correlated to p-mTOR, but were not correlated to the expression of ALK and p-AKT. Clinically, ALK + ALCL occurred more commonly in younger patients, and ALK + ALCL patients had a much better prognosis than ALK-ALCL cases. However, expression of p-AKT, p-mTOR, p-4E-BP1, or p-p70S6K1 did not have an impact on the clinical outcome. Overexpression of NPM-ALK in a nonmalignant murine pro-B lymphoid cell line, BaF3, induced the cells to become cytokine-independent and resistant to glucocorticoids (GCs). Targeting AKT/mTOR inhibited growth and triggered the apoptotic cell death of ALK + ALCL cells and NPM-ALK transformed BaF3 cells, and also reversed GC resistance induced by overexpression of NPM-ALK.

Conclusions

Overexpression of ALK due to chromosomal translocations is seen in the majority of ALCL patients and endows them with a much better prognosis. The AKT/mTOR signaling pathway is highly activated in ALK + ALCL patients and targeting the AKT/mTOR signaling pathway might confer a great therapeutic potential in ALCL.

Keywords

Anaplastic large cell lymphoma (ALCL) Anaplastic lymphoma kinase (ALK) AKT mTOR 4E-BP1 p-70S6K1 Prognosis

Background

Anaplastic large cell lymphoma (ALCL) is an aggressive form of non-Hodgkin’s lymphoma (NHL) of T/null lineage. It constitutes approximately 5% of all human NHL, but accounts for as many as 30% to 40% of pediatric large cell lymphomas [1]. Roughly 50 to 70% of ALCL patients carry characteristic chromosomal translocations involving the anaplastic lymphoma kinase (ALK) gene on chromosome 2p23, resulting in ALK overexpression due to the abnormal fusion of ALK with other genes [2]. The most common of these aberrations is the t(2;5)(p23;q35), which leads to the expression of the chimeric protein nucleophosmin-ALK (NPM-ALK). The others express variant fusions that, like NPM-ALK, involve the entire cytoplasmic portion of ALK, but fuse to other N-terminal partners, like tropomyosin 3 (TPM3) or 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) [35]. So far, at least 15 variant-ALK fusion genes have been identified in both hematopoietic malignancies, such as ALCL and diffuse large B cell lymphoma, and non-hematopoietic neoplasms, including inflammatory myofibroblastic tumor, esophagus cancer, and non-small cell lung cancer [611]. ALK immunostainning of NPM-ALK-positive ALCL cases shows a characteristic cytoplasmic and nuclear distribution of the chimeric ALK protein that is due to hetero-oligomerization of NPM-ALK and normal NPM, a phosphoprotein that normally shuttles ribonucleoproteins between the cytoplasm and nucleus, but can aberrantly transport NPM-ALK to the nucleus [12]; whereas patients with the variant-ALK fusion proteins demonstrate cytoplasmic staining only [13, 14]. In ALCL, ALK expression has a strong clinical prognostic significance. Compared with ALK negative (ALK-) ALCL, ALK positive (ALK+) ALCL occurs more frequently in younger patients who respond well to chemotherapy and have a favorable clinical outcome [1, 1519].

The mechanisms of cell transformation mediated by the ALK oncoprotein are only partially understood [5, 20, 21]. However, the NPM-ALK-induced activation of mammalian target of rapamycin (mTOR), either transduced through the mitogen-induced extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, or to a much less degree, through the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway has been shown to contribute to the tumorigenesis of ALCL [22, 23]. In ALK + ALCL cell lines and tumors, the mTOR signaling proteins, including mTOR, eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), and the 70 kDa ribosomal protein S6 kinase polypeptide 1 (p70S6K1) kinase are highly phosphorylated [23]. Inhibition of mTOR with rapamycin or silencing mTOR gene product expression using mTOR-specific small interfering RNAs decreased phosphorylation of the mTOR signaling proteins and induced cell cycle arrest and apoptosis in ALK + ALCL cells, indicating that blockage of the mTOR signaling pathway represents a potential therapeutic strategy in ALK + ALCL [22, 23]. Nevertheless, there is little evidence demonstrating the clinical prognostic value of the mTOR pathway activation in ALCL. In this relatively large case study, we showed that the AKT/mTOR pathway was highly activated in ALK + ALCLs compared with ALK- cases. Phosphorylation of AKT and mTOR was correlated to the expression of ALK, suggesting an activated ALK/AKT/mTOR pathway in ALK + ALCL; and this activation pathway was further confirmed by overexpression of NPM-ALK in the nonmalignant murine pro-B lymphoid cell line, BaF3. In contrast to ALK expression, expression of p-AKT, p-mTOR, p-4E-BP1, or p-p70S6K1 did not have any prognostic significance in ALCL; however, in vitro studies indicated that targeting the hyperactivated AKT/mTOR pathway effectively inhibited cell growth, triggered apoptosis, and reversed glucocorticoid (GC) resistance, suggesting an attractive therapeutic potential of AKT/mTOR inhibitors in ALCL.

Methods

Tumor samples

The tumor specimens were obtained from 103 patients with ALCL who underwent biopsy between January 2005 and October 2012 at the Department of Pathology, West China Hospital of Sichuan University, or the Department of Pathology, Shanghai Children’s Medical Center of Shanghai Jiaotong University. None of the patients had received any treatment before surgery. Tumor diagnosis was based on histological examination of tissue specimens obtained by biopsy and based on the criteria of the World Health Organization Classification. Written informed consent was obtained prior to sample collection from all patients or their parents if the patients were young children. This study was approved by the Institutional Review Board of the Ethical Committee of Sichuan University.

Immunohistochemical (IHC) studies

Rabbit polyclonal antibodies specific for Thr308p-AKT (p-AKT), Ser2448p-mTOR (p-mTOR), Thr70p-4E-BP1 (p-4E-BP1), and Thr421p-p70S6K1 (p-p70S6K1) (Cell Signaling Technology, Beverly, MA) were used. ALK expression was assessed initially by using rabbit polycloncal antibody ALK11 (a kind gift from Dr. Stephan W. Morris,St. Jude Children’s Research Hospital) and further confirmed by the mouse monoclonal antibody ALK-1 (Dako Cytomation, Carpinteria, CA) to exclude false positivity. IHC staining was performed to assess protein expression in formalin-fixed, paraffin embedded samples by the 2-step Envision procedure using a DAKO Autostainer (Dakopatts, Copenhagen, Denmark). The sections (6 μm) were de-paraffinized in xylene, dehydrated through a graded series of alcohol, and immersed for 15 min in phosphate-buffered saline (PBS). For antigen retrieval, sections were boiled in a pressure cooker for 4 min in 0.01 M citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked with 3% hydrogen peroxidase in methanol (10 min), and non-specific staining was then blocked with a 20 min incubation with normal horse serum. The sections were subsequently incubated overnight at 4°C with primary antibodies (ALK11, ×1000; ALK1, ×100; p-AKT, ×100; p-mTOR, ×100; p-4E-BP1, ×50; p-p70S6K1, ×25) in a humid chamber, treated for 30 min with a biotinylated horse secondary antibody against mouse immunoglobulins (ABC Elite; Vector, Burlingame, CA), and then exposed for 5 min to 0.06% diaminobenzidine with 0.01% hydrogen peroxidase. The sections were lightly counterstained with hematoxylin. Controls were performed by omitting the primary antibodies.

Evaluation of the IHC staining was performed in a blinded set up regarding the clinical data. Scoring of the expression was performed semiquantitatively. In brief, both percentage of stained cells and staining intensity were evaluated. No staining or weak staining in <10% of cells was defined as 0, weak staining in at least 10% as 1, moderate staining in up to 50% as 2 and moderate staining in >50% of cells and strong staining of any percentage of the cells as 3.

Overexpression of NPM-ALKin BaF3 cells and targeting of the AKT/mTOR pathway by kinase inhibitors

The murine pro-B cell, BaF3, and an ALK + ALCL cell line, Karpas 299, were kindly provided by Dr. Stephan W. Morris (St. Jude Children’s Research Hospital, Memphis, TN, USA). BaF3 cells (8 × 106) were electroporated with pcDNA3-NPM-ALK or empty vector (80 μg DNA, 975 μF, 270 V), then selected in IL-3-containing media with 1 mg/mL G418. G418-resistant pools were tested for NPM-ALK expression, and then seeded at 2 × 105 cells/mL in growth media with or without IL-3. BaF3/NPM-ALK and Karpas 299 cells were maintained in RPMI 1640 (Gibco. Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Sigma, St. Louis, MO, USA), 2 mM L-glutamine (Gibco), and antibiotics (penicillin 100 U/ml and streptomycin 50 μg/ml) at 37°C in a humidified 5% CO2 in-air atmosphere. BaF3 cells were cultured in the same media but with 10 ng/ml IL-3.

NVP-BEZ235 was provided by Novartis Pharma AG (Basel, Switzerland). For in-vitro use, NVP-BEZ235 was dissolved in DMSO (Sigma-Aldrich Corp., St. Louis, MO) to a stock concentration of 100 mmol/L, stored at −20°C, and further diluted to an appropriate final concentration in RPMI 1640 at the time of use. Dexamethasone ( Dex, Sigma, St Louis, MO, USA) was dissolved in ethanol and used at the concentration of 1 μM. Logarithmically growing cells were harvested and replated in 96- or 6-well sterile plastic culture plates (Corning) to which 1 mmol/L NVP-BEZ235 (NVP group), 1 μM dexamethasone (Dex group), 1 mmol/L NVP-BEZ235 plus 1 μM dexamethasone (NVP + Dex group), or 0.05% DMSO plus 0.1% ethanol (Con group) was added. At the end of the incubation, cells were transferred to sterile centrifuge tubes, pelleted by centrifugation at 400 g at room temperature for 5 min, and prepared for analysis as described below.

The MTT assay, used to determine the anti-proliferative effect of NVP-BEZ235 on cells growing in culture, together with the apoptosis assay and Western blotting analysis were performed as described previously (24).

Statistical analysis

Statistical analysis was carried out by using the SPSS 15.0 software package. Correlations between various parameters were calculated by Student’s t-test. Comparison of the expressions of the mTOR signaling proteins between ALK + and ALK- ALCL tumors was performed by chi- squared (χ2) test. The multivariate analysis was performed by the Cox proportional hazards model to identify subsets of independent prognostic factors for overall survival (OS). OS curves were estimated by using the Kaplan–Meier method and the log–rank test was used for comparing survival curves of the two groups. A p value < 0.05 was considered statistically significant. The analysis included mean values, standard deviation, standard error, and a 95% confidence interval.

Results

Histology and immunophenotyping of ALCL tumor samples

One hundred and three ALCL tumor samples were histologically divided into 3 types. Eighty cases (78%) were of common or classic type (Figure 1A), twenty (19%) were of small cell type (Figure 1B), and the remaining 2 (2%) cases were of lymphohistiocytic type. All tumor cells strongly expressed CD30. Seventy (68%) were of T-cell type expressing CD3 and/ or CD45RO and the other 33 were of null cell type expressing no T- or B- lineage markers. Eighty two (80%) expressed TIA1/Granzyme B and 62 (60%) cases expressed epithelial membrane antigen (EMA).
Figure 1

Histology and immunohistochemistry (IHC) of ALCL tumor samples. (A, B) Histology of ALCL tumor samples (HE staining). (A) The classic type of ALCL. The tumor cells are large with abundant cytoplasm and manifest prominent nucleoli with an eccentrically located and pleomorphic nucleus of kidney-shape. (B) ALCL of small cell type. The tumor cells are small in size, with abundant cytoplasm and prominent nucleoli. (C to H) IHC staining of ALCL tumor samples (EnVision staining). Expression of ALK, p-AKT, p-mTOR, p-4E-BP1, and p-p70S6K eIF4E was assessed. (C, D) IHC staining with ALK1 antibody. (C) The tumor cells show cytoplasmic and nuclear staining. (D) The tumor cells manifest cytoplasmic staining only. (E) IHC staining with Thr308p-AKT antibody. The tumor cells show cytoplasmic and nuclear staining. (F) IHC staining with Ser2448p-mTOR antibody. The tumor cells show cytoplasmic staining. (G) IHC staining with Thr70p-4E-BP1 antibody. The tumor cells show cytoplasmic staining. (H) IHC staining with Thr421p-p70S6K antibody. The tumor cells show cytoplasmic staining. All images were captured at 400× magnification.

Expression of ALK fusion proteins

In the 103 cases of ALCL, 62 (60%) were ALK positive, and either showed both cytoplasmic and nuclear staining indicative of the presence of NPM-ALK [49 cases, 79%, (Figure 1C), or cytoplasmic staining only indicating variant-ALK fusions 13 cases, 21%, (Figure 1D). Of the ALK + ALCL cases, the percentages of classic, histolymphocytic, and small cell type were 74%, 3%, and 23%, respectively. In the 41 ALK- ALCL patients, the percentages were 83%, 2%, and 15% respectively. There were no statistically significant differences of ALK expression between different histological subtypes of ALCL (χ2 = 0.642, p > 0.05).

Expression of p-AKT and its correlation to ALK expression

Immunostaining was performed with anti-p-AKT in 71 out of 103 cases of ALCL, 54 (76%) were positive (Figure 1E). In the 54 p-AKT positive (p-AKT+) cases, 38 (70%) were ALK + and 16 (27%) were ALK-. In the 17 p-AKT negative (p-AKT-) cases, 6 (35%) were ALK + and 11 (65%) were ALK-. Expression of p-AKT was correlated to ALK expression (×2 = 6.750, p < 0.05). In the 44 ALK + cases studied with p-AKT staining, 39 (87%) showed activation of AKT. In the 33 ALK + cases with both cytoplasmic and nuclear staining, 29 (88%) were p-AKT + and 4 (12%) were p-AKT-, and in the 11 cases with cytoplasmic staining only, 10 (91%) were p-AKT + and 1 (9%) was p-AKT-. The expression of p-AKT had no correlation to the different ALK expression (p > 0.05; Table 1).
Table 1

Relationship between p-AKT expression and ALK activation in ALCL

 

p-AKT + (n = 54)

p-AKT- (n = 17)

p-value

No. of patients

%

No. of patients

%

ALCL (n = 71)

     

 ALK+

38 of 54

70

6 of 17

35

 

 ALK-

16 of 54

30

11 of 17

65

0.009*

ALK + (n = 44)

     

 ALK (n + c)

29 of 39

74

4 of 5

80

 

 ALK (c)

10 of 39

26

1 of 5

20

0.779

* Statistically significant value.

ALK(n + c) indicates ALK + with both nucleus and cytoplasmic staining; ALK(c), ALK + with cytoplasmic staining only.

Expression of p-mTOR and its correlation to the expression of ALK and p-AKT

Immunostaining was performed with anti-p-mTOR in 71 cases, 57 (80%) were p-mTOR positive p-mTOR+, (Figure 1F), of which 39 (68%) were ALK+, and 18 (32%) were ALK-; 47 (82%) were p-AKT+, and 10 (18%) were p-AKT-. In the 14 p-mTOR negative (p-mTOR-) cases, 5 (36%) were ALK+, 9 (64%) were ALK-, 7(50%) were p-AKT+, and 7 (50%) were p-AKT-. Expression of p-mTOR was correlated to the expression of both ALK and p-AKT (×2 = 5.102 and 6.501 respectively, p < 0.05). In the 39 ALK + ALCL cases showing cytoplasmic and nuclear staining, 30 (91%) were p-mTOR+, and 3 (9%) were p-mTOR-, and in the 11 ALK + cases showing cytoplasmic staining only, 9 (82%) were p-mTOR + and 2 (18%) were p-mTOR-. The subcellular ALK expression patterns had no impact on the expression of p-mTOR in ALCL (χ2 = 0.619, p > 0.05; Table 2).
Table 2

Relationship between p-mTOR expression and activation of ALK and AKT

 

p-mTOR + (n = 57)

p-mTOR- (n = 14)

p-value

No. of patients

%

No. of patients

%

ALK (n = 71)

     

 ALK+

39 of 57

68

5 of 14

36

0.024*

 ALK-

18 of 57

32

9 of 14

64

 

p-AKT (n = 71)

     

 p-AKT+

47 of 57

83

7 of 14

50

0.011*

 p-AKT-

10 of 57

17

7 of 14

50

 

ALK + (n = 44)

     

 ALK(n + c)

30 of 39

77

3 of 5

60

0.431

 ALK(c)

9 of 39

23

2 of 5

40

 

*Statistically significant value.

Expression of p-4E-BP1 and p-p70S6K1

Sixty-four out of 71 (90%) ALCL tumors studied were p-4E-BP1 positive (p-4E-BP1+, Figure 1G), of which 40 (63%) were ALK+, 50 (78%) were p-AKT+, and 56 (88%) were p-mTOR+. In the 7 p-4E-BP1 negative (p-4E-BP1-) cases, 4 (57%) were ALK+, 4 (57%) were p-AKT+, and 1 (14%) was p-mTOR+. The expression of p-4E-BP1 had no correlation to that of ALK and p-AKT (χ2 = 0.783 and 1.359, respectively, p > 0.05), but was closely related to the expression of p-mTOR (χ2 = 16.531, p < 0.01).

Sixty-six of the 71 (93%) ALCL tumors were p-p70S6K1 positive (p-p70S6K1+, Figure 1H), of which 42 (64%) were ALK+, 51 (77%) were p-AKT+, and 55 (83%) were p-mTOR+. In the 5 p-p70S6K1 negative (p-p70S6K1-) cases, 2 (40%) were ALK+, 3 (60%) were p-AKT+, and 2 (40%) was p-mTOR+. The expression of p-p70S6K1 had no correlation to that of ALK and p-AKT (×2 = 0.119 and 0.684, respectively, p > 0.05), but was closely related to the expression of p-mTOR (χ2 = 4.295, p < 0.05; Table 3).
Table 3

Relationship between expression of p-4E-BP1 and p-p70S6K and activation of ALK, AKT, and mTOR

 

p-4E-BP1

p-value

p-p70S6K

p-value

+ (n = 64)

- (n = 7)

+ (n = 66)

- (n = 5)

ALK (n = 71)

      

 ALK+

40

4

 

42

2

 

 ALK-

24

3

0.783

24

3

0.119

p-AKT (n = 71)

      

 p-AKT+

50

4

 

51

3

 

 p-AKT-

14

3

0.244

15

2

0.408

p-mTOR (n = 71)

      

 p-mTOR+

56

1

 

55

2

 

 p-mTOR-

8

6

0.000*

11

3

0.038*

*Statistically significant value.

The interrelationship between the expression of ALK, p-AKT and p-mTOR and the clinical features

The median age of the 62 ALK + ALCL patients was 17 (4 ~ 68) years compared with 48 (16 ~ 74) years for the 41 ALK- cases. The age of onset was much younger in ALK + patients compared with ALK- cases (p < 0.01). In ALK + patients, 40 (65%) were male and 22 (35%) were female. In the 41 ALK- cases, 27 (66%) were male and 14 (34%) were female. Twenty-four (39%) of the ALK + patients had B symptoms compared with 14 (41%) of the ALK- cases. Fort-four (71%) ALK + patients had the primary lesion within the lymph node compared with 27 (66%) ALK- cases. Thirty-three (53%) ALK + patients were staging at III ~ IV compared with 20 (49%) ALK- cases. However, there were no statistical differences in sex distribution, clinical symptoms, primary lesion of the tumor, and Ann Arbor staging between ALK + and ALK- patients (p > 0.05).

The median age of the p-AKT + patients was 28 (4 ~ 74) years compared with 29 (4 ~ 65) years for the p-AKT- cases. In the 54 p-AKT + patients, 41 (76%) were male and 14 (24%) were female. In the 17 p-AKT- cases, 11 (82%) were male and 6 (18%) were female. Eighteen of the 54 (33%) p-AKT + patients had B symptoms compared with 6 of the 17 (36%) patients with p-AKT- tumors. Forty-two (78%) p-AKT + patients had the primary lesion within the lymph node compared with 12 (71%) p-AKT- cases. Twenty eight (52%) p-AKT + patients were staging at III ~ IV compared with 8 (47%) p-AKT- cases. There were no statistical differences in the age of onset, sex distribution, clinical symptoms, primary lesion of the tumor, and Ann Arbor staging between p-AKT + and p-AKT- patients (p > 0.05).

The median age of the 57 p-mTOR + patients was 25 (4 ~ 74) years compared with 40.5 (21 ~ 65) years of the 14 p-mTOR- cases. In the p-mTOR + patients, 44 (77%) were male and 13 (23%) were female, while in the 14 p-mTOR- cases, 11 (79%) were male and 6 (21%) were female. Twenty-two of the 57 (39%) p-mTOR + patients had B symptoms compared with 2 of the 14 (14%) patients with p-AKT- tumors. Forty-six (81%) p-mTOR + patients had the primary lesion within the lymph node compared with 8 (57%) p-mTOR- cases. Twenty-nine (51%) p-mTOR + patients were staging at III ~ IV compared with 7 (50%) p-mTOR- patients. Again, there was no statistical difference in the age of onset, sex distribution, clinical symptoms, primary lesion of the tumor, and Ann Arbor staging between p-mTOR + and p-mTOR- patients (p > 0.05).

On the whole, except that ALK + ALCL was predominantly seen at a younger age, there was no correlation between the expression of ALK, p-AKT, p-mTOR and its two downstream molecules, p-4E-BP1 and p-70S6K1, and the risk factors of the age of onset, sex distribution, clinical B symptoms, primary lesion of the tumor, and the Ann Arbor stage of the disease (Table 4).
Table 4

Relationship between the activation status of ALK, AKT and mTOR and the clinical features

 

ALK

p-value

p-AKT

p-value

p-mTOR

p-value

+ (n = 62)

- (n = 41)

+ (n = 54)

- (n = 17)

+ (n = 57)

- (n = 14)

Age (years)

         

 Median

17

48

 

28

29

 

25

40.5

 

 Range

4–68

16–74

0.000*

4–74

4–65

0.877

4–74

21–65

0.076

Gender

         

 Male

40

27

 

41

14

 

44

11

 

 Female

22

14

0.889

13

3

0.573

13

3

0.912

Symptoms

         

 A

38

26

 

36

11

 

35

12

 

 B

24

15

0.828

18

6

0.889

22

2

0.068

Lesions

         

 Nodal

44

27

 

42

12

 

46

8

 

 Extranodal

18

14

0.583

12

5

0.547

11

6

0.07

Ann Arbor stage

         

 I ~ II

29

21

 

26

9

 

28

7

 

 III ~ IV

33

20

0.659

28

8

0.730

29

7

0.953

*Statistically significant value.

Symptom B, systemic symptoms of fever, night sweats, and weight loss; Symptom A, absence of the systemic symptoms.

The prognostic significance of the expression of ALK, p-AKT, p-mTOR, p-4E-BP1, and p-p70S6K1

Follow-up study was carried out in 70 of the 103 (68%) patients. The follow-up time was from 0.3 to 96.0 months. The survival time for ALK + patients ranged from 0.6 to 96.0 months and the median time was 27.0 months, with an expected 5-year survival rate of over 67%. The survival time for ALK- patients ranged from 0.3 ~ 28.0 months, with the median time of 4.0 months and a 2-year survival rate of 20%. The prognosis of ALK + patients was much better than that of ALK- cases. The difference was statistically significant (p < 0.01, Figure 2A), but there was no difference in the cumulative survival rate between NPM-ALK + ALCL patients and those with variant ALK fusions (Figure 2B). Compared with ALK expression, neither the expression of p-AKT, p-mTOR, p-4E-BP1, nor p-p70S6K1 had statistically significant differences regarding the median survival time and the 5-year survival rate in the ALCL patients.
Figure 2

Comparison of overall survival time in ALK + and ALK- ALCL patients. (A) Kaplan-Meier curves showing significant difference in cumulative survival rate between ALK + and ALK- ALCL patients. (B) Kaplan-Meier curves showing no difference in cumulative survival rate between NPM-ALK + ALCLs and those ALCLs with variant ALK fusions.

Among other risk factors, including sex, age, primary lesion of the tumor (nodal or extranodal), Ann Arbor staging, histology, B symptoms, and immunological phenotype, only B symptoms had prognostic significance. By using Cox proportional hazards model analysis, only the expression of ALK and B symptoms had statistical significance on the prognosis (p < 0.05), of which the former had a greater impact than the latter.

Overexpression of NPM-ALK activated the AKT/mTOR pathway in BaF3 cells and induced drug resistance to Dex and targeting AKT/mTOR re-sensitized the cell to Dex treatment

Expression of NPM-ALK converted BaF3 cells from IL-3 dependent to cytokine-independent growth, indicating a strong transforming activity of the kinase (Figure 3A). Interestingly, expression of NPM-ALK also conferred resistance to GC treatment. Compared with BaF3 cells transfected with empty vector, the transformed cells grew well at 1 μM Dex (Figure 3B) and could even survive at a concentration of Dex as high as 500 μM (data not shown). Western blotting analysis indicated the overexpression of NPM-ALK induced hyper-activation of the AKT/mTOR pathway in BaF3 cells, as demonstrated by hyperphosphorylation of AKT and downstream molecules of mTOR: 4E-BP1 and p70SK6 (Figure 4). Both Dex and the dual PI3K/mTOR inhibitor, NVP-BEZ235, had little effect on cell growth, but when they were used in combination a strong synergistic inhibitory effect was produced in ALK + cells, especially in the NPM-ALK transformed BaF3 cells (Figure 5A). Interestingly, when the kinase inhibitor was used in combination with Dex, it triggered apoptosis and convert the transformed BaF3/NPM-ALK cells re-sensitive to GC treatment (Figure 5B). The similar result was achieved when mTOR inhibitor rapamycin was used (data not shown).
Figure 3

Overexpression of NPM-ALK in BaF3 cells induced their cytokine independent growth and resistance to dexamethasone treatment. (A) NPM-ALK confers IL-3-independent growth to BaF3 cells. Stably transfected BaF3 cells expressing NPM-ALK were assessed for growth in the presence or absence of IL-3, together with empty vector-containing cells. Viable cell counts were performed in triplicate using trypan blue at 24-hour intervals, with each point being the average of the triplicate measurements. (B) BaF3 cells transformed by NPM-ALK became resistant to GCs and could survive well in 1 μM Dex, while BaF3 cells transfected with empty vector could not proliferate at this concentration.

Figure 4

Overexpression of NPM-ALK activated the AKT/mTOR pathway. Overexpression of NPM-ALK in BaF3 cells induced hyper-activation of the AKT/mTOR pathway, as demonstrated by hyperphosphorylation of AKT and downstream molecules of mTOR: 4E-BP1 and p70SK6.

Figure 5

Targeting AKT/mTOR had a therapeutic significance on ALK + tumor cells. (A) Synergistic growth inhibition between the dual PI3K/mTOR inhibitor, NVP-BEZ235, and Dex in all cells, especially in BaF3/NPM-ALK. (B) A higher apoptosis rate in cells treated with NVP-BEZ235 and Dex together compared with single use of the drugs.

Discussion and conclusions

Anaplastic lymphoma kinase was first discovered by Dr. Morris and colleagues in 1994 due to its involvement in the t(2;5) chromosomal translocation in ALCL [24]. Since ALK expression is normally restricted to neural tissues, immunostainning of ALCL with ALK-specific antibodies becomes a quick, convenient, and also a reliable means to identify ALK + tumors. Large clinico-pathologic studies of ALCL have shown that about 80% of cases of ALK + ALCL exhibit cytoplasmic and nuclear staining indicative of the presence of NPM-ALK; whereas the remaining 20% express ALK proteins only in the cytoplasm of the tumor cells, indicating variant-ALK fusions [1, 13, 25]. Our study showed that 60% of ALCL tumors had ALK positive staining, of which 79% demonstrated a NPM-ALK staining pattern and 21% showed the staining pattern of variant-ALK fusions, which correlated well to the results in the literature [13, 25, 26]. We did not find any correlation between ALK expression and the histological subtype. In regard to the prognosis, there was no statistical difference between the patients with NPM-ALK and variant-ALK fusions. These data suggest that ALK + ALCLs have the same pathogenesis no matter what kind of ALK fusion partners they have.

The mean age of the 62 patients with ALK + ALCLs was 25 ± 15 years compared with 46 ± 17 years for the 41 ALK- cases. The former was much younger than the latter, p < 0.05. Although in our case there was a higher percentage of patients who had B symptoms and the primary lesion within the lymph nodes, or had the diseases at stage III ~ IV in ALK + than ALK- ALCLs, there was no statistical significance, p > 0.05. However, follow-up study indicated that ALK + ALCL patients had a much better prognosis than that of ALK- cases. The 5-year survival rate of ALK + cases was over 60%, whereas the 2-year survival rate for ALK- cases was only 20%. Kaplan-Meier curve and log-rank test showed that ALK + ALCL patients had a significantly better cumulative survival than ALK- ALCL cases (p < 0.05). This result is much corroborated by case studies elsewhere [1316, 26], except for the survival time. In our study the overall 5-year survival rate was 52% for all ALCL patients, 67% for ALK + cases, and less than 20% for ALK- patients compared with 77% for the total ALCLs, 80% for ALK + ALCLs, and 40% for ALK- ALCLs reported [7, 8, 2527]. The cause for this difference is now under investigation.

Compiling evidence demonstrates that oncogenic NPM-ALK kinase induces the activation of mTOR signaling pathway, which contributes to NPM-ALK/PI3K/AKT-mediated tumorigenesis in ALCL, and that inhibition of AKT/mTOR represents a potential therapeutic strategy in ALK + ALCL [9, 10, 28]. In this study, activation of ALK/AKT/mTOR pathway was checked in 71 out of the 103 ALCL patient tumor samples. We found that the AKT/mTOR pathway was highly activated in ALK + ALCL. Phosphorylation of Thr308p-AKT and Ser2448p-mTOR was detected at higher percentages in ALK + ALCL tumors and their activation was closely related to ALK expression, but not related to its expression pattern, suggesting that no matter what the ALK fusions they are, they can activate the AKT/mTOR pathway. Our in vitro study also confirmed that NPM-ALK had strong transforming activity in lymphocytes and overexpression of NPM-ALK could induce the activation of the AKT/mTOR signaling pathway.

Activation of the AKT/mTOR pathway has been associated with aggressive disease and poor prognosis in certain cancers, like breast cancer [2933]. However, currently there is little information on the prognostic value of the activation of the AKT/mTOR pathway in ALCL. We checked the phosphorylation status of AKT, mTOR, and its two downstream effectors, p70S6K1 and 4E-BP1, and studied its correlation with clinical risk factors. Compared with ALK expression, expression of p-AKT, p-mTOR, p-p70S6K1 and p-4E-BP1 had no correlation with clinical features such as age, sex, symptoms, primary lesions and tumor staging, or overall survival, indicating that activation of the AKT/mTOR pathway had no prognostic value in ALCL. However, our in vitro study indicated that inhibition of the AKT/mTOR pathway could effectively reverse the GC resistance induced by overexpression of NPM-ALK in lymphocytes. Considering GC is the most commonly used and highly effective drug used for decades in the treatment of lymphoid malignancies, targeting AKT/mTOR might be an attractive therapeutic goal in the future.

In summary, we have shown that the AKT/mTOR pathway was highly activated in ALK + ALCL. However, activation of this pathway does not confer any prognostic significance in ALCL as in some other tumors [3437]. However, this does not compromise the therapeutic importance of blocking the AKT/mTOR pathway in this disease considering that activation of AKT/mTOR leads to resistance to chemo-reagents [38] and glucocorticoids [39] which constitute the first choice for the treatment of lymphoid malignancies including ALCL. Clinical use of AKT/mTOR inhibitors in the treatment of ALCL should be further explored.

Abbreviations

ALCL: 

Anaplastic large cell lymphoma

ALK: 

Anaplastic lymphoma kinase

NPM: 

Nucleophosmin

mTOR: 

Mammalian target of rapamycin

MEK: 

Mitogen-induced extracellular kinase

ERK: 

Extracellular signal-regulated kinase

PI3K: 

Phosphatidylinositol 3-kinases

AKT: 

Protein kinase B

GC: 

Glucocorticoid

4E-BP1: 

4E-binding protein-1

p70S6K1: 

70 kDa ribosomal protein S6 kinase polypeptide 1

TPM3: 

Tropomyosin 3

ATIC: 

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

IHC: 

Immunohistochemical

EMA: 

Epithelial membrane antigen

PBS: 

Phosphate-buffered saline

Dex: 

Dexamethasone

OS: 

Overall survival.

Declarations

Acknowledgements

This work was supported by the National Natural Science Foundation of China (0040215401097 and 30973237).

Authors’ Affiliations

(1)
Department of Pediatrics, West China Second University Hospital, Sichuan University
(2)
Department of Pathology, Shanghai Children’s Medical Center, Shanghai Jiaotong University

References

  1. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, Delsol G, Mason D: Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997, 89: 1394-1404.PubMedGoogle Scholar
  2. Morris SW, Xue L, Ma Z, Kinney MC: Alk + CD30+ lymphomas: a distinct molecular Genetic subtype of non-hodgin lymphoma. Br J Hematol. 2001, 113: 275-295. 10.1046/j.1365-2141.2001.02574.x.View ArticleGoogle Scholar
  3. Lamant L, Dastugue N, Pulford K, Delsol G, Mariamé B: A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood. 1999, 93: 3088-3095.PubMedGoogle Scholar
  4. Ma ZG, Cools J, Marynen P, Cui XL, Siebert R, Gesk S, Schlegelberger B, Peeters B, Wolf-Peeters CD, Wlodarska I, Morris SW: Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood. 2000, 95: 2144-2149.PubMedGoogle Scholar
  5. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008, 8: 11-23. 10.1038/nrc2291.View ArticlePubMedGoogle Scholar
  6. Feldman AL, Vasmatzis G, Asmann YW, Davila J, Middha S, Eckloff BW, Johnson SH, Porcher JC, Ansell SM, Caride A: Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. Genes Chromosomes Cancer. 2013, 52: 1097-1102.View ArticlePubMedGoogle Scholar
  7. Cessna MH, Zhou H, Sanger WG, Perkins SL, Tripp S, Pickering D, Daines C, Coffin CM: Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol. 2002, 15: 931-938. 10.1097/01.MP.0000026615.04130.1F.View ArticlePubMedGoogle Scholar
  8. Jazii FR, Najafi Z, Malekzadeh R, Conrads TP, Ziaee AA, Abnet C, Yazdznbod M, Karkhane AA, Salekdeh GH: Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol. 2006, 12: 7104-7112.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Soda M, Choi YL, Enomoto M, Takade S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007, 448: 561-566. 10.1038/nature05945.View ArticlePubMedGoogle Scholar
  10. Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G: Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol. 2011, 47: R11-R23. 10.1530/JME-11-0004.View ArticlePubMedGoogle Scholar
  11. Takeuchi K, Soda M, Togashi Y, Ota Y, Sekiguchi Y, Hetano S, Asaka R, Noguchi M, Mano H: Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica. 2011, 96: 464-467. 10.3324/haematol.2010.033514.View ArticlePubMedGoogle Scholar
  12. Bischof D, Pulford K, Mason DY, Morris SW: Role of the nucleophosmin (NPM) portion of the non-hodgkin’s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997, 17: 2312-2325.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugières L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G: ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998, 91: 2076-2084.PubMedGoogle Scholar
  14. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A: ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999, 93: 2697-2706.PubMedGoogle Scholar
  15. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large-cell lymphoma. Blood. 1999, 93: 3913-3921.PubMedGoogle Scholar
  16. Sandlund JT, Pui CH, Roberts WM, Santana VM, Morris SW, Berard CW, Hutchison RE, Ribeiro RC, Mahmoud H, Crist WM: Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood. 1994, 84: 2467-2471.PubMedGoogle Scholar
  17. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, Mori N, Fujimoto J, Miyauchi J, Mikata A: Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995, 86: 1954-1960.PubMedGoogle Scholar
  18. Ferreri AJ, Govi S, Pileri SA, Savage KJ: Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol. 2013, 85: 293-302.View ArticleGoogle Scholar
  19. Ferreri AJ, Govi S, Pileri SA, Savage KJ: Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol. 2013, 85: 206-215. 10.1016/j.critrevonc.2012.06.004.View ArticlePubMedGoogle Scholar
  20. Li RS, Morris SW: Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev. 2008, 28: 372-412. 10.1002/med.20109.View ArticlePubMedGoogle Scholar
  21. Amin HM, Lai R: Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007, 110: 2259-2267. 10.1182/blood-2007-04-060715.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA: Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene. 2007, 26: 5606-5614. 10.1038/sj.onc.1210346.View ArticlePubMedGoogle Scholar
  23. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ: Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006, 66: 6589-6597. 10.1158/0008-5472.CAN-05-3018.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Thomas Look A: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in Non-Hodgkin’s lymphoma. Science. 1994, 263: 1281-1284. 10.1126/science.8122112.View ArticlePubMedGoogle Scholar
  25. Falini B, Pulford K, Pucciarini A, Carbone A, Wolf-Peeters CD, Cordell J, Fizzotti M, Santucci A, Pelicci PG, Pileri S, Campo E, Ott G, Delsol G, Mason DY: Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood. 1999, 94: 3509-3515.PubMedGoogle Scholar
  26. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolinl B, Billi M, Pucciarini A, Pacini R, Pelicci PG, Flenghi L: ALK expression defines a distinct group of T/null lymphomas (“ALK lymphomas”) with a wide morphological spectrum. Am J Pathol. 1998, 153: 875-886. 10.1016/S0002-9440(10)65629-5.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Wang FH, Li YH, Zeng J, Rao HL, Xia ZJ, Sun XF, Huang HQ, Lin TY, Jiang WQ, Guan ZZ: Clinical analysis of primary systemic anaplastic large cell lymphoma: a report of 57 cases. Chin J Cancer. 2009, 28: 49-53.Google Scholar
  28. Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF, Tripp SR, Rassidakis GZ, Medeiors LJ, Szankasi P, Elenitoba-Johnson KSJ: The proteomic signature of NPM-ALK reveals deregulation of multiple cellular pathways. Blood. 2009, 114: 1585-1595. 10.1182/blood-2009-02-204735.View ArticlePubMedGoogle Scholar
  29. Lee DF, Hung MC: All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle. 2007, 6: 3011-3014. 10.4161/cc.6.24.5085.View ArticlePubMedGoogle Scholar
  30. Albanell J, Dalmases A, Rovira A, Rojo F: mTOR signaling in human cancer. Clin Transl Oncol. 2007, 9: 484-493. 10.1007/s12094-007-0092-6.View ArticlePubMedGoogle Scholar
  31. Seelinger H, Guba M, Kleespies A, Jauch KW, Bruns CJ: Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastasis, and angiogenesis. Cancer Metastasis Rev. 2007, 26: 611-621. 10.1007/s10555-007-9077-8.View ArticleGoogle Scholar
  32. Ghayad SE, Cohen PA: Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov. 2010, 5: 29-57. 10.2174/157489210789702208.View ArticlePubMedGoogle Scholar
  33. Awada A, Cardoso F, Fontaine C, Dirix L, Grève JD, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M: The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer. 2008, 44: 84-91. 10.1016/j.ejca.2007.10.003.View ArticlePubMedGoogle Scholar
  34. Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F: The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer. 2009, 8: 75-View ArticlePubMedPubMed CentralGoogle Scholar
  35. Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ, Qualman S, Tsokos M, Krishnan K, Helman LJ, Liotta LA: Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Cancer Res. 2007, 67: 3431-3440. 10.1158/0008-5472.CAN-06-1344.View ArticlePubMedGoogle Scholar
  36. Pelloski CE, Lin E, Zhang L, Alfred Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG, Fuller GN, Aldape KD: Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006, 12: 3935-3941. 10.1158/1078-0432.CCR-05-2202.View ArticlePubMedGoogle Scholar
  37. Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM, Paik NS: Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat. 2008, 110: 447-483.View ArticleGoogle Scholar
  38. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA: The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 2010, 1: 89-103.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Gu L, Gao J, Li Q, Zhu YP, Jia CS, Fu RY, Chen Y, Liao QK, Ma ZG: Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Leukemia. 2008, 22: 2091-2096. 10.1038/leu.2008.204.View ArticlePubMedGoogle Scholar
  40. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/471/prepub

Copyright

© Gao et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.